GNFT Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 366.09%. Given that DBV Technologies SA has higher upside potential than Genfit SA, analysts believe DBV Technologies SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$30.4M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Genfit SA's net margin of -48.85%. Genfit SA's return on equity of -- beat Edap TMS SA's return on equity of -42.5%.

Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand Edap TMS SA has an analysts' consensus of $10.67 which suggests that it could grow by 365.79%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.782%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.4M. Genfit SA's net income of -- is lower than Edap TMS SA's net income of -$7M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus 1.24x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -- compared to Genfit SA's net margin of -64.14%. Genfit SA's return on equity of -- beat Evaxion Biotech AS's return on equity of --.

Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 608.56%. Given that Evaxion Biotech AS has higher upside potential than Genfit SA, analysts believe Evaxion Biotech AS is more attractive than Genfit SA.

Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Evaxion Biotech AS quarterly revenues of $3M. Genfit SA's net income of -- is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus 0.52x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

TC BioPharm (Holdings) PLC has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.

Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2642.86%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Genfit SA, analysts believe TC BioPharm (Holdings) PLC is more attractive than Genfit SA.

Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Genfit SA pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. Genfit SA's net income of -- is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.